Held by 4 specialist biotech funds
High Convergence# Signal Note: RA Capital Initiates $321M Position in Tyra Biosciences RA Capital's substantial entry into TYRA signals conviction in the company's TYR-286 (selective TrkC inhibitor) pipeline, likely driven by upcoming Phase 2 data in neuropathic pain and potential label expansion beyond its current colorectal cancer indication. Kolchinsky's involvement suggests confidence in Tyra's mechanism and commercial opportunity, though near-term catalysts and clinical readouts will be critical to validate this thesis.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free TrialKaplan sold ~$529K in TYRA shares at ~$37, representing a meaningful disposition for a director-level insider. Without context on remaining holdings, this could reflect routine diversification or a planned 10b5-1 sale, but the size warrants monitoring — particularly if other insiders follow. Director sales in small-cap biotech ahead of clinical readouts tend to carry more signal than in large-caps; worth cross-referencing against upcoming data catalysts and any recent filing amendments.